OZEM Roundhill GLP-1 & Weight Loss ETF

ETF on NASDAQ (US) · Actively managed · Listing

Daily holdings file Nov 17, 2026 Published at roundhillinvestments.com
Book $55.8M 24 positions
Line items 24
In top 10 72%
Largest holding: Eli Lilly and Company ($11.4M) 20.5%
Portfolio date Nov 17, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Eli Lilly and Company, 8,083 shares ($11.4M).

Eli Lilly and Company: 20.5% Novo Nordisk A/S: 10.9% Chugai Pharmaceutical Co., Ltd.: 7.2% HanmiPharm: 6.9% Pfizer, Inc.: 5.8% Kailera Therapeutics, Inc.: 4.6% Cspc Pharmaceutical Group Limited: 4.6% Jiangsu Hengrui Pharmaceuticals Co Ltd: 4.1% Hansoh Pharmaceutical Group Co Ltd: 3.8% Viking Therapeutics, Inc.: 3.7% The other 14 positions: 27.8% $55.8M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $11.4M 20.5%
Novo Nordisk A/S NVO $6.10M 10.9%
Chugai Pharmaceutical Co., Ltd. 4519 $4.02M 7.2%
HanmiPharm 128940 $3.85M 6.9%
Pfizer, Inc. PFE $3.22M 5.8%
Kailera Therapeutics, Inc. KLRA $2.58M 4.6%
Cspc Pharmaceutical Group Limited 1093 $2.57M 4.6%
Jiangsu Hengrui Pharmaceuticals Co Ltd 1276 $2.31M 4.1%
Hansoh Pharmaceutical Group Co Ltd 3692 $2.10M 3.8%
Viking Therapeutics, Inc. VKTX $2.09M 3.7%

Slices are % of holdings value.

Healthcare: 96.2% Unclassified: 3.8% 1 sectors
Sectors % of long value
Healthcare 96.2%
Unclassified 3.8%
Drug Manufacturers - General: 68.8% Biotechnology: 27.4% Unclassified: 3.8% 2 industries
Industries % of long value
Drug Manufacturers - General 68.8%
Biotechnology 27.4%
Unclassified 3.8%

Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (roundhillinvestments.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The Fund seeks to provide capital appreciation.

Principal investment strategies

The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss ("GLP-1 & Weight Loss Drugs"). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration ("FDA") clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA ("GLP-1 & Weight Loss Companies"). For non-U.S. companies that are not subject to oversight by the FDA, the Fund may classify such company as a GLP-1 & Weight Loss Company if that company's GLP-1 & Weight Loss Drug is currently undergoing clinical trials subject to regulatory oversight by that company's applicable food and drug regulator or if that company's GLP-1 & Weight Loss Drug has been approved by the company's applicable food and drug regulator. The Fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies. In seeking to achieve the Fund's investment objective, the Fund's investment adviser, Roundhill Financial Inc. ("Roundhill" or the "Adviser"), constructs the Fund's portfolio pursuant to its own proprietary security selection methodology. In general, the methodology prioritizes companies with higher levels of "thematic relevance," which is based upon research on individual companies' public disclosures (e.g., 10-K filings, company presentations, capital markets day presentations, etc.) and other publicly available sources (e.g., sell-side research, biotechnology industry publications, drug development pipeline trackers, etc.). The Fund will also only invest in those companies with a minimum market capitalization of $100 million and an average daily trading volume of $500,000. The Adviser rebalances the weighting of the companies comprising the Fund's portfolio on at least a quarterly basis. The Fund may invest in U.S. and non-U.S. companies (including those operating in developed or emerging market countries) through investments in depositary receipts, American Depositary Receipts ("ADRs") or Global Depositary Receipts ("GDRs"), including depositary receipts whose underlying securities are non-voting preferred securities. Such companies will be small-, mid- and large-capitalization issuers. The Fund will concentrate (i.e., invest more than 25% of its total assets) its investments in the industry or group of industries comprising the health care sector. As of March 31, 2026, the Fund had significant investments in European companies. To the extent the Fund invests a significant portion of its assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investment sector. The Fund is classified as "non-diversified" under the Investment Company Act of 1940 (the "1940 Act").

Management and Contact

Adviser
Roundhill Financial Inc.
Sub-adviser
Exchange Traded Concepts, LLC
Portfolio managers

The individuals primarily responsible for the day-to-day management of the Fund are Timothy Maloney (Roundhill), William Hershey (Roundhill), David Mazza (Roundhill), Andrew Serowik (ETC), Todd Alberico (ETC), Gabriel Tan (ETC) and Brian Cooper (ETC).

Messrs. Serowik, Alberico, Tan and Cooper served as portfolio managers since 2024 and Messrs. Maloney, Hershey and Mazza have served as portfolio managers since 2025.

Phone
(855) 561-5728

Holdings as of Nov 17, 2026

24 lines, 20 linked, weights sum to 99.98% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
Eli Lilly & Co LLY 532457108 Equity 8,083 0 20.49% $ 11.442M
Novo Nordisk A/S NVO 670100205 Equity 149,897 0 10.92% $ 6.101M
Chugai Pharmaceutical Co Ltd 4519 JP 6196408 Equity 87,300 0 7.20% $ 4.023M
Hanmi Pharm Co Ltd 128940 KS B613DJ9 Equity 11,503 0 6.90% $ 3.855M
Pfizer Inc PFE 717081103 Equity 113,197 0 5.77% $ 3.223M
Kailera Therapeutics Inc KLRA 482931102 Equity 211,629 0 4.62% $ 2.582M
CSPC Pharmaceutical Group Ltd 1093 HK 6191997 Equity 2,560,000 0 4.61% $ 2.574M
Jiangsu Hengrui Pharmaceuticals Co Ltd 1276 HK BMV9P26 Equity 380,200 0 4.14% $ 2.309M
Hansoh Pharmaceutical Group Co Ltd 3692 HK BJYKB72 Equity 494,000 0 3.77% $ 2.104M
Viking Therapeutics Inc VKTX 92686J106 Equity 77,574 0 3.73% $ 2.085M
AstraZeneca PLC AZN G0593M107 Equity 10,026 0 3.27% $ 1.827M
Ascletis Pharma Inc 1672 HK BFLTDL2 Equity 3,227,000 0 3.21% $ 1.795M
Zealand Pharma A/S ZEAL DC B0SDJB4 Equity 50,254 0 3.04% $ 1.699M
Amgen Inc AMGN 031162100 Equity 3,689 0 3.02% $ 1.689M
Roche Holding AG
ROP SW BTMJD19 Equity 3,213 0 2.79% $ 1.555M
Structure Therapeutics Inc GPCR 86366E106 Equity 85,120 0 2.77% $ 1.547M
Gubra A/S GUBRA DC BMZQSP7 Equity 27,580 0 2.10% $ 1.173M
United Laboratories International Holdings Ltd/The 3933 HK B1P70H9 Equity 1,222,000 0 2.05% $ 1.143M
Innovent Biologics Inc 1801 HK BGR6KX5 Equity 95,000 0 1.86% $ 1.039M
MBX Biosciences Inc MBX 55287L101 Equity 18,003 0 1.71% $ 955.959K
Gilead Sciences Inc GILD 375558103 Equity 4,756 0 1.45% $ 809.757K
First American Government Obligations Fund 12/01/2031
FGXXX 31846V336 Money market 398,085.19 −2,283,550.95 0.71% $ 398.085K
SWISS FRANC
CHF CASHCHF Equity short -215,321.29 −398,430.19 -0.46% $ -256.625K
Cash & Other
CASH&OTHER CASH&OTHER Cash 173,610.55 +1,156,573.14 0.31% $ 173.611K

Trades Nov 16, 2026 to Nov 17, 2026

Holding Ticker Action Before After Change Value
SOUTH KOREA WON
KRW Closed -2,265,723,960 — +2,265,723,960 $ 1.696M
SWISS FRANC
CHF Sold 183,108.9 -215,321.29 −398,430.19 $ -474.859K
DANISH KRONE
DKK Closed 668,881.02 — −668,881.02 $ -98.481K

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up